ATLANTA, GA, November 29, 2016 /24-7PressRelease/
-- The MNG Carrier Exome (https://mnglabs.com/providers/mng-carrier-screen/
) is a unique, complete test to determine carrier status for recessive disorders like cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, to name a few, for prospective parents of any ethnicity. The test is designed to detect a wide range of rare family or sub-population specific variants that could have an adverse effect in offspring.
Rather than focusing solely on known pathogenic variants that are common in well characterized populations, the MNG Carrier Exome provides a comprehensive range of coverage for those seeking a more thorough review versus standard carrier screening tests. Whole exome sequencing is performed on both partners in order to detect shared known pathogenic and predicted disruptive variants in genes that are causative of autosomal recessive disorders. This test is intended for prospective parents who are interested in the most complete review of their genetic background to better understand their risk of having children with rare autosomal recessive disorders. It is not recommended for diagnostic purposes.
"This is an innovative approach to the carrier screen market and marks an important product development success for MNG as we expand our product line," explains Terry Conrad, Chief Executive Officer of MNG Laboratories. "We are a leading neurogenetic laboratory committed to delivering answers no one else can and our MNG Carrier Exome complements our proven line up of NGS Panels and well recognized neurochemical tests."
In a recent Genome Medicine article, Dr. Arthur Beaudet, the Henry and Emma Meyer Chair and Professor of Molecular and Human Genetics at Baylor College of Medicine outlined a vision for the future of genetic carrier testing and noted the urgent need for strategies to present a range of options to families to enable them to make informed decisions1. In a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation and Society for Maternal-Fetal Medicine the group noted that expanded carrier screening can provide information about carrier status beyond population estimates and eliminates the need for ethnicity-based screening2.
"The MNG Carrier Exome is a testament to the commitment of our lab team to offer innovation and flexibility to help prevent fatal, severe, untreatable, difficult to manage genetic disorders," noted Peter L. Nagy, Chief Medical Officer of MNG Laboratories. "This supports our goal to deliver the quality answers our customers expect to help improve their patient's quality of life".
In addition to the unique MNG Carrier Exome , MNG Laboratories is launching a Pan-European Carrier Screen test and an Ashkenazi Jewish Carrier Screen test. Both are well known test categories with MNG Laboratories utilizing next generation sequencing technology to meet the demands of its customers to provide highly specific and sensitive test results.
More information about MNG Laboratories can be found at mnglabs.com.
1) Reference: Global genetic carrier testing: a vision for the future. Arthur L. Beaudet. Genome Medicine (2015) 7:79
2) Reference: Expanded Carrier Screening in Reproductive Medicine - Points to Consider. Janice G. Edwards, et. Al. Obstetrics & Gynecology 2015
About MNG Laboratories
MNG Laboratories is a leading provider of neurogenetic testing through clinical services, complex biochemical testing and sequencing. Our extensive offering of Next Generation Sequencing panels is recognized by genetic experts around the world. Combined with our validated proprietary Genome MaNaGer database and variant calling methods, our Neurogenetic Answers platform delivers first-in-class reporting and fast turnaround times. We specialize in cellular energetics defects, muscular dystrophies, epilepsy, intellectual disabilities and cardiomyopathy. Powered by a culture of discovery and advancement, MNG Laboratories seeks to make a difference for clients with life-changing scientific challenges.
Terry J. Conrad